Ensysce Biosciences, Inc. – NASDAQ:ENSC
Ensysce Biosciences stock price today
Ensysce Biosciences stock price monthly change
Ensysce Biosciences stock price quarterly change
Ensysce Biosciences stock price yearly change
Ensysce Biosciences key metrics
Market Cap | 10.63M |
Enterprise value | 1.93M |
P/E | -0.03 |
EV/Sales | N/A |
EV/EBITDA | -0.05 |
Price/Sales | N/A |
Price/Book | -0.17 |
PEG ratio | N/A |
EPS | -3.95 |
Revenue | 1.74M |
EBITDA | -9.98M |
Income | -11.54M |
Revenue Q/Q | -61.28% |
Revenue Y/Y | -35.54% |
Profit margin | 0% |
Oper. margin | 0% |
Gross margin | 0% |
EBIT margin | 0% |
EBITDA margin | -571.96% |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeEnsysce Biosciences stock price history
Ensysce Biosciences stock forecast
Ensysce Biosciences financial statements
| Jun 2023 | 490.47K | -2.23M | -455.88% |
|---|---|---|---|
| Sep 2023 | 435.38K | -2.68M | -617.75% |
| Dec 2023 | 515.03K | -3.50M | -680.4% |
| Mar 2024 | 305.72K | -3.11M | -1019.39% |
| Mar 2024 | 305.72K | -3.11M | -1019.39% |
|---|---|---|---|
| Sep 2025 | 5.56M | -1.29M | -23.21% |
| Oct 2025 | 5.26M | -1.76M | -33.56% |
| Dec 2025 | 7.24M | -1.62M | -22.4% |
Analysts Price target
Financials & Ratios estimates
| Payout ratio | 0% |
|---|
| 2019 | |
|---|---|
| 2020 | |
| 2021 | 56496.11% |
| 2022 | 3.76% |
| 2023 |
| Jun 2023 | 6357623 | 2.56M | 40.34% |
|---|---|---|---|
| Sep 2023 | 3218686 | 2.06M | 64.03% |
| Dec 2023 | 2708085 | 3.35M | 124.05% |
| Mar 2024 | 5074190 | 1.65M | 32.59% |
| Jun 2023 | -3.10M | 0 | 5.52M |
|---|---|---|---|
| Sep 2023 | -2.26M | 0 | -102.45K |
| Dec 2023 | -1.80M | 0 | 1.46M |
| Mar 2024 | -3.40M | 0 | 5.68M |
Ensysce Biosciences alternative data
| Aug 2023 | 7 |
|---|---|
| Sep 2023 | 7 |
| Oct 2023 | 7 |
| Nov 2023 | 7 |
| Dec 2023 | 7 |
| Jan 2024 | 7 |
| Feb 2024 | 7 |
| Mar 2024 | 7 |
| Apr 2024 | 7 |
| May 2024 | 7 |
| Jun 2024 | 7 |
| Jul 2024 | 7 |
Ensysce Biosciences other data
| Period | Buy | Sel |
|---|---|---|
| Jun 2020 | 0 | 776290 |
| Insider | Compensation |
|---|---|
Dr. D. Lynn Kirkpatrick Ph.D. (1957) Pres, Chief Executive Officer & Director | $155,870 |
Mr. Richard Wright M.B.A., MSE (1972) Chief Bus. Officer | $76,000 |
Mr. Geoffrey Birkett (1962) Chief Commercial Officer | $72,000 |
-
What's the price of Ensysce Biosciences stock today?
One share of Ensysce Biosciences stock can currently be purchased for approximately $2.04.
-
When is Ensysce Biosciences's next earnings date?
Unfortunately, Ensysce Biosciences's (ENSC) next earnings date is currently unknown.
-
Does Ensysce Biosciences pay dividends?
No, Ensysce Biosciences does not pay dividends.
-
How much money does Ensysce Biosciences make?
Ensysce Biosciences has a market capitalization of 10.63M and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 11.61% to 2.23M US dollars.
-
What is Ensysce Biosciences's stock symbol?
Ensysce Biosciences, Inc. is traded on the NASDAQ under the ticker symbol "ENSC".
-
What is Ensysce Biosciences's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Ensysce Biosciences?
Shares of Ensysce Biosciences can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Ensysce Biosciences's key executives?
Ensysce Biosciences's management team includes the following people:
- Dr. D. Lynn Kirkpatrick Ph.D. Pres, Chief Executive Officer & Director(age: 68, pay: $155,870)
- Mr. Richard Wright M.B.A., MSE Chief Bus. Officer(age: 53, pay: $76,000)
- Mr. Geoffrey Birkett Chief Commercial Officer(age: 63, pay: $72,000)
-
How many employees does Ensysce Biosciences have?
As Jul 2024, Ensysce Biosciences employs 7 workers.
-
When Ensysce Biosciences went public?
Ensysce Biosciences, Inc. is publicly traded company for more then 7 years since IPO on 14 Mar 2018.
-
What is Ensysce Biosciences's official website?
The official website for Ensysce Biosciences is ensysce.com.
-
Where are Ensysce Biosciences's headquarters?
Ensysce Biosciences is headquartered at 7946 Ivanhoe Avenue, La Jolla, CA.
-
How can i contact Ensysce Biosciences?
Ensysce Biosciences's mailing address is 7946 Ivanhoe Avenue, La Jolla, CA and company can be reached via phone at 858 263 4196.
Ensysce Biosciences company profile:
Ensysce Biosciences, Inc.
ensysce.comNASDAQ
7
Biotechnology
Healthcare
Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, engages in developing various prescription drugs for severe pain relief in opioid addiction, misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection platform, an abuse-resistant opioid prodrug technology; and Multi-Pill Abuse Resistance platform, an over-dose protection opioid prodrug technology. The company is developing PF614, a TAAP prodrug candidate of oxycodone, which is in Phase II clinical trial for the treatment of acute or chronic pain; and PF614-MPAR, a combination product of PF614 and nafamostat that is in Phase I clinical trial for overdose protection against excessive oral ingestion, as well as an oral and inhalation drug product of nafamostat for use against coronaviral infections and other pulmonary diseases, such as cystic fibrosis. It is also developing PF329, an extended-release prodrug of hydromorphone that is similar to PF614; PF8001 and PF8026 are extended and immediate-release prodrugs of amphetamine for ADHD medication abuse; and PF26810, an extended-release prodrug of methadone for opioid use disorder. The company is based in La Jolla, California.
La Jolla, CA 92037
CIK: 0001716947
ISIN: US2936024056
CUSIP: 293602108
